{"id":1877,"date":"2025-11-19T13:08:01","date_gmt":"2025-11-19T13:08:01","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:08:01","modified_gmt":"2026-06-26T13:08:01","slug":"amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/","title":{"rendered":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque"},"content":{"rendered":"\n<p><strong>Montr\u00e9al, Qu\u00e9bec<\/strong>&nbsp;<strong>\u2013 19 novembre 2025&nbsp;<\/strong>\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour le traitement des arythmies cardiaques h\u00e9r\u00e9ditaires, des maladies cardiom\u00e9taboliques et des cardiomyopathies, a annonc\u00e9 aujourd\u2019hui la nomination de Amy Rudolph, PhD, \u00e0 son conseil d\u2019administration. La Dre Rudolph apporte plus de 25 ans d\u2019exp\u00e9rience en leadership dans l\u2019industrie pharmaceutique mondiale, avec une expertise approfondie couvrant la d\u00e9couverte, le d\u00e9veloppement clinique, les affaires m\u00e9dicales et l\u2019acc\u00e8s au march\u00e9.&nbsp;<\/p>\n\n\n\n<p>La Dre Rudolph occupe actuellement le poste de Head of Global Medical Affairs and Cross-TA Medical Affairs chez Boehringer Ingelheim, o\u00f9 elle dirige une transformation mondiale visant \u00e0 b\u00e2tir une organisation d\u2019affaires m\u00e9dicales de premier plan ax\u00e9e sur l\u2019engagement externe, l\u2019int\u00e9gration num\u00e9rique\/IA, la g\u00e9n\u00e9ration de donn\u00e9es, les analyses avanc\u00e9es et le d\u00e9veloppement des comp\u00e9tences.&nbsp;<\/p>\n\n\n\n<p>\u00ab Nous sommes ravis d\u2019accueillir Amy Rudolph au sein de notre conseil d\u2019administration \u00bb, a d\u00e9clar\u00e9 Paul Truex, pr\u00e9sident et chef de la direction de Th\u00e9rapeutiques Thryv. \u00ab Son exp\u00e9rience approfondie en affaires m\u00e9dicales, en g\u00e9n\u00e9ration de donn\u00e9es et en d\u00e9veloppement de m\u00e9dicaments interfonctionnels sera inestimable alors que nous faisons progresser notre portefeuille d\u2019inhibiteurs de SGK1 vers des \u00e9tudes cliniques de phases avanc\u00e9es. \u00bb&nbsp;<\/p>\n\n\n\n<p>\u00ab Nous sommes \u00e9galement tr\u00e8s reconnaissants envers Scott Weiner pour ses nombreuses contributions au conseil d\u2019administration \u00bb, a ajout\u00e9 M. Truex. \u00ab Nous sommes heureux qu\u2019il reste \u00e9troitement impliqu\u00e9 aupr\u00e8s de Thryv \u00e0 titre de conseiller. \u00bb&nbsp;<\/p>\n\n\n\n<p>Avant de se joindre \u00e0 Boehringer Ingelheim, la Dre Rudolph a occup\u00e9 des postes de direction chez Novartis Pharmaceutical Corporation, o\u00f9 elle a \u00e9t\u00e9 Head of HCS Partnerships au sein du Global Drug Development et Head of Evidence and Launch Excellence au sein des affaires m\u00e9dicales mondiales. Plus t\u00f4t dans sa carri\u00e8re, elle a occup\u00e9 des postes cl\u00e9s chez Pfizer Inc., o\u00f9 elle \u00e9tait responsable des plateformes d\u2019ath\u00e9roscl\u00e9rose et d\u2019AVC, du d\u00e9veloppement pr\u00e9coce et des \u00e9valuations de licences\/technologies, apr\u00e8s avoir d\u00e9but\u00e9 sa carri\u00e8re scientifique chez G.D. Searle\/Pharmacia\/Pfizer.&nbsp;<\/p>\n\n\n\n<p>Au cours de sa carri\u00e8re, la Dre Rudolph a jou\u00e9 un r\u00f4le cl\u00e9 dans le d\u00e9veloppement et le lancement de plusieurs th\u00e9rapies cardiovasculaires, notamment Inspra, Eliquis, Lipitor, Diovan, Diovan\/HCT, Exforge, Tekturna et Entresto, ainsi que dans le d\u00e9veloppement de Serelaxin et Amturnide.&nbsp;<\/p>\n\n\n\n<p>La Dre Rudolph a obtenu son doctorat en biochimie et biologie mol\u00e9culaire de l\u2019Universit\u00e9 Washington \u00e0 St. Louis et est l\u2019inventrice de 13 brevets ainsi que de nombreuses publications scientifiques couvrant la recherche pr\u00e9clinique, le d\u00e9veloppement de m\u00e9dicaments et les donn\u00e9es en conditions r\u00e9elles.&nbsp;<\/p>\n\n\n\n<p>\u00ab Je suis honor\u00e9e de rejoindre le conseil d\u2019administration de Th\u00e9rapeutiques Thryv \u00bb, a d\u00e9clar\u00e9 Amy Rudolph. \u00ab La science de Thryv et sa mission centr\u00e9e sur les patients r\u00e9sonnent profond\u00e9ment avec mes valeurs, et je suis impatiente de soutenir les progr\u00e8s continus de l\u2019entreprise dans le traitement de maladies cardiovasculaires graves. \u00bb&nbsp;<\/p>\n\n\n\n<p>La Dre Rudolph rejoint le conseil alors que Scott Weiner, qui y si\u00e8ge depuis 2021, passe \u00e0 un r\u00f4le d\u2019observateur. M. Weiner demeurera membre du conseil d\u2019administration de la filiale de la soci\u00e9t\u00e9, Thryv Therapeutics USA, Inc., tout en continuant de servir comme conseiller aupr\u00e8s de l\u2019entreprise.&nbsp;<\/p>\n\n\n\n<p><strong>\u00c0 propos de la plateforme d\u2019inhibiteurs de SGK1 de Thryv<\/strong>&nbsp;<\/p>\n\n\n\n<p>Th\u00e9rapeutiques Thryv fait progresser un portefeuille d\u2019inhibiteurs puissants et s\u00e9lectifs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) qui ciblent les m\u00e9canismes fondamentaux \u00e0 l\u2019origine du remodelage \u00e9lectrique et structurel du c\u0153ur. THRV-1268, le principal candidat clinique de la soci\u00e9t\u00e9, est un inhibiteur de SGK1 hautement s\u00e9lectif et le meilleur de sa cat\u00e9gorie, avec le potentiel de transformer le paysage th\u00e9rapeutique du syndrome du QT long (LQTS), de l\u2019insuffisance cardiaque (IC) et de la fibrillation auriculaire (FA) \u2014 trois affections cardiaques graves avec des besoins m\u00e9dicaux non satisfaits urgents.&nbsp;<\/p>\n\n\n\n<p><strong>\u00c0 propos de Th\u00e9rapeutiques Thryv<\/strong>&nbsp;<\/p>\n\n\n\n<p>Th\u00e9rapeutiques Thryv Inc. est une soci\u00e9t\u00e9 priv\u00e9e bas\u00e9e \u00e0 Montr\u00e9al, Qu\u00e9bec, Canada. Thryv est \u00e0 la pointe d\u2019une approche de m\u00e9decine de pr\u00e9cision visant \u00e0 traiter les canalopathies g\u00e9n\u00e9tiques, les maladies cardiom\u00e9taboliques et les cardiomyopathies gr\u00e2ce \u00e0 des inhibiteurs puissants et s\u00e9lectifs de s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1). Pour plus d&#8217;informations, veuillez visiter le site&nbsp;<a href=\"http:\/\/www.thryvtrx.ca\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.thryvtrx.ca<\/a>.&nbsp;&nbsp;<\/p>\n\n\n\n<p><strong>Demandes des m\u00e9dias<\/strong>&nbsp;<\/p>\n\n\n\n<p><a href=\"mailto:brittany@thryvtrx.com?\" target=\"_blank\" rel=\"noreferrer noopener\">brittany@thryvtrx.com<\/a>&nbsp;| 514 973 0915&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/thryvtrx.ca\/fr\/nouvelles\/amy-rudolph-rejoint-thryv\">Lire le communiqu\u00e9 original<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 19 novembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[124],"class_list":["post-1877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare\" \/>\n<meta property=\"og:description\" content=\"Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 19 novembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T13:08:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque\",\"datePublished\":\"2025-11-19T13:08:01+00:00\",\"dateModified\":\"2026-06-26T13:08:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/\"},\"wordCount\":830,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/\",\"name\":\"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"datePublished\":\"2025-11-19T13:08:01+00:00\",\"dateModified\":\"2026-06-26T13:08:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare","og_description":"Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 19 novembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/","og_site_name":"adMare","article_published_time":"2025-11-19T13:08:01+00:00","article_modified_time":"2026-06-26T13:08:01+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque","datePublished":"2025-11-19T13:08:01+00:00","dateModified":"2026-06-26T13:08:01+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/"},"wordCount":830,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/","name":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","datePublished":"2025-11-19T13:08:01+00:00","dateModified":"2026-06-26T13:08:01+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1877"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1877\/revisions"}],"predecessor-version":[{"id":1879,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1877\/revisions\/1879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1878"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1877"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}